戻る
Akero Therapeutics Inc (AKRO)価格
AKRO 株価推移チャート
AKRO 収入
Akero Therapeutics Inc
$54.65
0%
$0
終値： Feb 06, 16:00:00 GMT-5
$54.65
0%
$0
アフターマーケット：Feb 06, 20:00:00 GMT-5
最新の利益結果: Q3 '25
報告済み: 2025-11-07
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
AKROの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Akero Therapeutics Inc AKROの前四半期の収益はどうでしたか？
Akero Therapeutics Incの収益見積もりはいくらですか？
Akero Therapeutics Incの収益品質スコアはどれくらいですか？
Akero Therapeutics Incはいつ収益を報告しますか？
Akero Therapeutics Incの予想収益はいくらですか？
Akero Therapeutics Incは収益予想を上回りましたか？
主要データ
前終値
$54.65
始値
$54.52
当日レンジ
$54.42 - $54.82
52週レンジ
$21.34 - $58.4
取引高
11.6M
平均取引高
2.1M
1株当たり利益(TTM)
-3.75
配当利回り
--
時価総額
$4.4B
AKROとは何ですか？
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The company is headquartered in South San Francisco, California and currently employs 74 full-time employees. The company went IPO on 2019-06-20. Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.